Mona Saraiya, MD, MPH

Mona Saraiya, MD, MPH, leads the global cancer portfolio at CDC since 2010. She has been serving in the role as Associate Director in the Division of Cancer Prevention and Control’s (DCPC’s) Office of International Cancer Control since 2014. Prior to her current position, Dr. Saraiya served as a medical officer and worked on domestic issues related to skin cancer epidemiology and cervical cancer prevention and control. Her cervical cancer and human papillomavirus (HPV) research portfolio includes an initiative to characterize the HPV-associated cancer burden in the United States, and adherence to cervical cancer screening guidelines, especially with newer technologies such as HPV testing.

She graduated from Rush Medical College, completed a Masters of Public Health at Emory School of Public Health, completed a residency in Preventive Medicine/Public Health, and is board certified by the American College of Preventive Medicine.

Dr. Saraiya is an alumna of the Epidemic Intelligence Service program, an adjunct professor at Emory University and at Morehouse School of Medicine, and has published more than 150 articles during her tenure at CDC.

Dr. Saraiya provided CDC Expert Commentary for Medscape on Clearing Up Confusion About Cervical Cancer Screening.

Some of the most recent articles Dr. Saraiya has authored include—

• 2016 Importance of economic evaluation of cancer registration in the resource limited setting: Laying the groundwork for surveillance systems.
• 2015 U.S. assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
• 2015 A door-to-door approach to cervical cancer screening.
• 2015 Evidence is lacking to support pelvic examinations as a screening tool for non-cervical cancers or other conditions.
• 2014 Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.
• 2014 A need for improved understanding about USPSTF and other evidence-based recommendations.
• 2013 Evolution of cervical cancer screening and prevention in the United States and Canada.
• 2012 Cancers that U.S. physicians believe the HPV vaccine prevents: Findings from a physician survey, 2009.
• 2011 Cervical cancer screening among women who attend sexually transmitted disease (STD) clinics: background paper for 2010 STD treatment guidelines.
• 2011 HPV vaccine effect: is the glass half full or half empty? [comment]
• 2010 Ambulatory care visits for Pap tests, abnormal Pap test results, and cervical cancer procedures in the United States.
• 2010 Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries.
• 2010 Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs. Papanicolaou testing alone: what screening intervals are physicians recommending?
• 2010 Common abnormal results of Pap and human papillomavirus cotesting: what physicians are recommending for management.
• 2009 Liquid-based cytology vs conventional cytology in detecting cervical cancer.
• 2009 Pap testing and sexual activity among young women in the United States.
• 2009 Specialty differences in primary care physician reports of Papanicolaou test screening practices: a national survey, 2006 to 2007.
• 2008 Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role.
• 2008 Incidence of in situ and invasive vulvar cancer in the U.S., 1998–2003.
• 2008 Toward using National Cancer Surveillance data for preventing and controlling cervical and other human papillomavirus-associated cancers in the U.S.
• 2007 Cervical cancer incidence in a prevaccine era in the United States, 1998–2002.
• 2007 Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
• 2007 Sunburn prevalence among adults—United States, 1999, 2003, and 2004.
• 2005 Total and percent free prostate-specific antigen levels among U.S. men, 2001–2002.
• 2004 Cervical cancer screening among women without a cervix.
• 2004 Interventions to prevent skin cancer by reducing exposure to ultraviolet radiation: A systematic review.
• 2004 Skin cancer screening among U.S. adults from 1992, 1998, and 2000 National Health Interview Surveys.
• 2003 Preventing skin cancer: Findings of the Task Force on Community Preventive Services on reducing exposure to ultraviolet light.
• 2002 Observations from the CDC: An assessment of Pap smears and hysterectomies among women in the United States.
• 2002 Sunburn prevalence among adults in the United States, 1999.
• 2001 Self-reported Papanicolaou smears and hysterectomies among women in the United States.
• 2001 The role of family history in personal and clinical cancer prevention practices among U.S. women physicians.
• 2000 Personal and clinical skin cancer prevention practices of U.S. women physicians.

Dr. Saraiya is featured in the following podcasts—

• Pap Tests and Foreign-Born Women
• Cervical Cancer
• Women: Be Aware
• Natural History of HPV and Cervical Cancer
• Costs Associated with Cervical Cancer Screening
• Management of Cervical Cytology with HPV Test
• Cervical Cancer Screening with HPV Test
• HPV Testing Among Providers
• ACOG Recommendations and Guidelines for Cervical Cancer Screening and Management
• Case Studies: Cervical Cancer
• Cervical Cancer Screening in Underserved Populations
• Future Directions: Cervical Cancer